BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 20535959)

  • 1. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
    Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome: an emerging target for cancer therapy.
    Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
    Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing bortezomib with chemotherapy and targeted agents.
    Adjei AA
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
    Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
    Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Ishii Y; Waxman S; Germain D
    Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
    Colland F
    IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
    [No Abstract]   [Full Text] [Related]  

  • 20. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.